Vigilant Biosciences releases oral cancer diagnostic in Germany

Vigilant Biosciences, an innovator and developer of solutions that assist in the early detection of oral cancer, has released its breakthrough product, the BeVigilant OraFusion System, in Germany.

The BeVigilant OraFusion System provides a tool to assist in oral cancer detection by determining the presence of specific biomarkers and integrating intelligent software to assess clinical risk factors. Early detection, as seen in Stage 1 or Stage 2 diagnosis, can result in significantly improved outcomes, with survival rates soaring as high as 90%. The current survival rate for oral cancer stands at just 50%, often due to late-stage detection and intervention.

Bill Brodie, CEO of Vigilant Biosciences, said: "Our mission has always been to improve survival outcomes in oral cancer through early detection. With the introduction of the BeVigilant OraFusion System in Germany, we're bringing this mission to life, offering hope to those impacted by this disease. We believe that through our technological advances, we can save lives by changing the face of oral cancer detection."

While oral cancer can present noticeable or bothersome symptoms even in its initial stages, early diagnoses remain a challenge often due to limitations in current dental screening methods. Healthcare practitioners do aim to evaluate oral lesions rigorously, although they may sometimes struggle to accurately identify them as malignant early on. Unfortunately, this results in a wait-and-watch strategy. When the disease is diagnosed at a later stage, patients may need extensive surgical intervention, which can lead to a reduced quality of life. However, advances in diagnostic technology can assist healthcare practitioners in making earlier and more accurate diagnoses, thereby increasing the chances of effective treatment and potentially improving patient outcomes.